Despite President Donald Trump’s White House having scrapped a plan that would have eliminated rebates for some drugs under Medicare, pressure to find solutions to high prices will remain, a recent Deloitte blog post suggests.
The pharmaceutical industry, the author writes, should also take steps to develop a new model to address drug prices rather than waiting for the government to step in.
“Pharmaceutical companies might want to evaluate clinical outcomes to demonstrate superiority in class, improvements in standard of care, or efficacy within specific patient sub-populations,” the post states. “As value-based contracts become more common, manufacturers should demonstrate the value of new products or product classes.”
To read the full post on Deloitte, click here.